valganciclovir

(redirected from Valcyte)
Also found in: Dictionary.

valganciclovir

 [val″gan-si´klo-vir]
a prodrug of ganciclovir, used in treatment of cytomegalovirus infections in immunocompromised patients; administered orally as the hydrochloride salt.

valganciclovir

/val·gan·ci·clo·vir/ (val″gan-si´klo-vir) a prodrug of ganciclovir, used as the hydrochloride salt in the treatment of cytomegalovirus retinitis in patients with AIDS.

valganciclovir

[val′gan-si′klo-vir]
a prodrug of ganciclovir, used in treatment of cytomegalovirus infections in immunocompromised patients and administered orally as the hydrochloride salt.

valganciclovir

A pro-drug of GANCICLOVIR used to treat CYTOMEGALOVIRUS INFECTION especially with retinitis. A brand name is Valcyte.
References in periodicals archive ?
Valcyte is a registered trademark of Genentech, Inc.
The supplemental approval is based on data that showed longer prophylactic treatment with Valcyte reduced the incidence of CMV disease in high risk adult kidney transplant patients from 36.
I have had to keep patients in the hospital for two or three days until the state approved their Valcyte prescriptions.
Pender, following his EBV-infected B cell model of autoimmunity, has had marginal success using the herpes class drugs Valcyte, Valtrex, Acyclovir, and so on.
Roche USA, Nutley, NJ, announced the FDA has approved Valcyte (valganciclovir hydrochloride) for the prevention of cytomegalovirus (CMV) disease in pediatric kidney and heart transplant patients--4 months to 16 years of age--at high risk of developing CMV disease.
Tenders are invited for Medicinal Products with Valcyte Concluding Framework Agreements
Currently, Roche's Valcyte is the only branded drug available for the treatment of this indication.
Nutley, NJ, has received approval from the US Food and Drug Administration (FDA) for Valcyte for the prevention of cytomegalovirus (CMV) disease in high-risk kidney, kidney-pancreas and heart transplant patients.
Food and Drug Administration (FDA) approved increasing the length of therapy with Valcyte (valganciclovir hydrochloride) in adult kidney transplant patients at high risk for cytomegalovirus (CMV) disease.
MEDICATIONS: Mabthera, ROACTEMRA, Valcyte, Pulmozyme.
Roche Holding AG, Basel, Switzerland, announced that the Mutual Recognition Procedure has been completed, and approved by the European Union (EU), for Valcyte (valganciclovir) for the prevention of cytomegalovirus (CMV) disease, a potentially fatal infection that affects solid organ transplant recipients.
3 million grant from Roche Pharmaceutical, which manufactures the drug under the brand name Valcyte, to conduct a randomized, placebo-controlled, double-blind study set to begin this quarter at Stanford.